Sounds of Science – Episode 6 Overcoming Barriers: Improving Access for Rare Disease Patients through Cross-Border Healthcare The Cross-Border Healthcare Directive (Directive 2011/24/EU) marked a milestone for European patients. It created a legal framework for the patientâs right to seek healthcare in another Member State… read more
As the science around genomics continues to evolve, advanced diagnostics technologies are delivering benefits to todayâs patients while supporting future research and clinical development. However, beyond research programmes, many of these technologies are not reaching patients in clinical routine care in Europe. Patientsâ health outcomes… read more
EUCOPE’s latest position paper outlines our vision for the evolution of the EU Regulatory framework and a modernisation of the Centralised Procedure to ultimately bring novel medicines earlier to patients. The European Centralised Procedure (CP) has helped and accelerated the approval of novel medicines across… read more
EUCOPE, in partnership with Sanofi, participated in the European Health Forum Gastein 2021 (EHFG) on 29 September in a session on rare diseases to discuss what is needed to stimulate basic research, clinical development, and access to care across the EU in light of the… read more
EUCOPE, in partnership with the Swedish Industry Association for Small and Medium-Sized Life Sciences Companies (IML), hosted a roundtable on the Revision of the European Orphan & Paediatric Regulation with Nordic stakeholders on 7 September. Over the last 20 years, the orphan and paediatric legislation… read more
The European Commission is consulting stakeholders as part of its revision process of two major pieces of legislation, on medicines for rare diseases and paediatric patients. Central to the development of innovative treatments for these specific categories of patients, this revision process represents an important… read more
The European Commission has launched an evaluation of the Orphan Medicinal Product (OMP) and Paediatric Regulations. EUCOPE seizes the opportunity to outline ways to strengthen the EU environment for the development of rare and paediatric disease treatments, of which the Regulation (EC) No 1901/2006 on… read more
The European Commission launched an evaluation of the legislation on medicines for rare diseases and children. EUCOPE seizes the opportunity to outline ways to strengthen the whole EU environment for the development of rare diseases treatments, of which the Regulation (EC) No 141/2000 on orphan… read more
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
The Genomics Working Group is made up of advanced diagnostics companies that have come together to ensure Europe will be able to draw benefit from the significant advances that have been made in genomic testing. The group aims to facilitate a dialogue around these technologies… read more
Keep up-to-date on all of the most pertinent policy files and regulatory news around the world of European health technologies with our monthly newsletter â the Innovation Eye-View